GIP and GLP-1 receptor co-agonist
CT-388 5.0 mg injection
CT388_SC_5p0MG_OTHER
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.44 (0.01 to 15.49) | 0.66 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 0.23 (0.00 to 4.73) | 0.91 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 6.22 (0.59 to 61.27) | 0.39 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.23 (0.00 to 4.19) | 0.87 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.21 (0.00 to 4.39) | 0.86 |